Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SIgnatera-Guided Initiation of Adjuvant CDK4/6 Inhibitor in Intermediate Risk HR+ HER2- Breast Cancer

NCT07214532 is registered in ClinicalTrials.gov with Natera, Inc. as lead sponsor.

NCT NCT07214532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07214532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SIgnatera-Guided Initiation of Adjuvant CDK4/6 Inhibitor in Intermediate Risk HR+ HER2- Breast Cancer
Lead sponsor
Natera, Inc.
Phase
Not applicable
Overall status
Recruiting
Start date
May 8, 2026
Completion date
December 30, 2037
Enrollment
725 (estimated)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, carcinoma, ductal, breast, receptors, estrogen (for er-positive requirement)